<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347586">
  <stage>Registered</stage>
  <submitdate>13/10/2011</submitdate>
  <approvaldate>1/11/2011</approvaldate>
  <actrnumber>ACTRN12611001139965</actrnumber>
  <trial_identification>
    <studytitle>Difference between Heparin and Enoxaparin on inflammatory biomarkers in the treatment of heart attack (myocardial infarction).</studytitle>
    <scientifictitle>Comparison between Heparin and Enoxaparin on inflammatory biomarkers (IL6, hs-CRP, MPO, SAA and ferritin) in STEMI.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>STEMI</healthcondition>
    <healthcondition>inflammatory cytokin</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm1: STEMI patients ,Intravenous bolus Heparin(60 IU/kg followed by 1000 IU per hour continuous infusion to achieve an aPTT of 50-75 seconds,48 hours)The minimum duration of heparin therapy after MI is generally 48 hours, but it may be longer, depending on the individual clinical scenario.
Arm 2: STEMI patients ,enoxaparin (1mg/kg sub cutaneous every 12 hr ,48 hours)The minimum duration of enoxaparintherapy after MI is generally 48 hours, but it may be longer, depending on the individual clinical scenario.</interventions>
    <comparator>Arm1: STEMI patients ,Intravenous bolus Heparin(60 IU/kg followed by 1000 IU per hour continuous infusion to achieve an aPTT of 50-75 seconds,48 hours)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>changes in inflammatory biomarkers (IL6, hs-CRP, MPO, SAA and ferritin) in plasma of STEMI pateints following anticuagolant therapy.</outcome>
      <timepoint>0,12,24,48 hours after starting administration of Heparin or Enoxaparin</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age &gt;18
patients with definite STEMI diagnosis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1-history of AMI or CHF or AF
2-history of liver( LFT&gt; 3ULN), kidney(Cr&gt;2 or Cr &gt; 25% increase in baseline),thyroid disease or malignancy
3-acute or chronic infection or autoimmune disease 
4- treatment with heparin or enoxaparin before study
5-pregnancy or breastfeeding
6-treatment with anti-inflammatory drug during 3 mounths ago</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran university of medical science</primarysponsorname>
    <primarysponsoraddress>16 Azar AVE,Tehran university of medical science,faculty of pharmacy ,Tehran,Iran,1417614411</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Tehran university of medical science</fundingname>
      <fundingaddress>16 Azar AVE,Tehran university of medical science,faculty of pharmacy ,Tehran,Iran,1417614411</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>IL6,CRP,SSA  and MPO have a important role in a diagnosis and prediction of mortality in myocardial infarction(MI).some studies have mentioned the anti-inflammatory effect of heparin and enoxaparin.There is no study that is shown which drug has a better effect in decreasing inflammatory bio markers.
The primary purpose of this study is to find that if  enoxaparin and heparin can reduce inflammatory factors and which drug has a better effect in decreasing that bio markers?</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>pharmaceutical Science Reasearch center</ethicname>
      <ethicaddress>16 Azar AVE,pharmaceutical Science Reasearch center,Tehran,1417614411.</ethicaddress>
      <ethicapprovaldate />
      <hrec>89-1</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mojtahedzadeh,Mojtaba</name>
      <address>16 Azar AVE,Tehran university of medical science ,faculty of pharmacy,Tehran,1417614411</address>
      <phone>+98, 912,1056032</phone>
      <fax>+98,21,66954709</fax>
      <email>Mojtahed@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mojtahedzadeh,Mojtaba</name>
      <address>16 Azar AVE,Tehran university of medical science ,faculty of pharmacy,Tehran,1417614411</address>
      <phone>+98, 912,1056032</phone>
      <fax>+98,21,66954709</fax>
      <email>Mojtahed@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>nasiripour, Somayeh</name>
      <address>16 Azar AVE,Tehran university of medical science ,faculty of pharmacy,Tehran,1417614411</address>
      <phone>+98 912 3259306</phone>
      <fax>+98,21,66954709</fax>
      <email>snasiripour@razi.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>